BrainStorm Cell Therapeutics to Present at Biotech Showcase™ 2023

Rhea-AI Summary

On January 5, 2023, BrainStorm Cell Therapeutics (NASDAQ: BCLI) announced that its management will present a corporate and clinical overview at Biotech Showcase™ 2023 on January 9 at 10:30 a.m. PT in San Francisco. Presenters include President and CEO Chaim Lebovits and Co-CEO Stacy Lindborg. Attendees can join in person or via webcast. The company specializes in adult stem cell therapies for neurodegenerative diseases, with its NurOwn® technology receiving orphan drug designation for treating ALS.

NEW YORK, Jan. 5, 2023 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced that Chaim Lebovits, President and CEO, and Stacy Lindborg, Co-CEO, will jointly present a corporate and clinical overview at 10:30 a.m. PT on Monday, Jan. 9 at Biotech Showcase™ 2023 (Hilton San Francisco Union Square, Yosemite A, Ballroom Level). Company management will also be available for one-on-one investor meetings at the conference, which can be requested via the Biotech Showcase platform.

Registered attendees may attend the presentation in-person or view it via webcast through the Biotech Showcase platform.

Those interested in registering for Biotech Showcase may do so using the link, here.

About BrainStorm Cell Therapeutics Inc. 

BrainStorm Cell Therapeutics Inc. is a leading developer of innovative autologous adult stem cell therapeutics for debilitating neurodegenerative diseases. The Company holds the rights to clinical development and commercialization of the NurOwn^® technology platform used to produce autologous MSC-NTF cells through an exclusive, worldwide licensing agreement. Autologous MSC-NTF cells have received Orphan Drug designation status from the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) for the treatment of amyotrophic lateral sclerosis (ALS). BrainStorm has completed a Phase 3 pivotal trial in ALS (NCT03280056); this trial investigated the safety and efficacy of repeat-administration of autologous MSC-NTF cells and was supported by a grant from the California Institute for Regenerative Medicine (CIRM CLIN2-0989). BrainStorm completed under an investigational new drug application a Phase 2 open-label multicenter trial (NCT03799718) of autologous MSC-NTF cells in progressive MS and was supported by a grant from the National MS Society (NMSS).

Safe-Harbor Statement       

Statements in this announcement other than historical data and information, including statements regarding BrainStorm's Type A meeting with the FDA and the clinical development of NurOwn^® as a therapy for the treatment of ALS, constitute "forward-looking statements" and involve risks and uncertainties that could cause BrainStorm Cell Therapeutics Inc.'s actual results to differ materially from those stated or implied by such forward-looking statements. Terms and phrases such as "intend," "should," "could," "will,"  "believe," "potential," and similar terms and phrases are intended to identify these forward-looking statements. The potential risks and uncertainties include, without limitation, management's ability to successfully achieve its goals, BrainStorm's ability to raise additional capital, BrainStorm's ability to continue as a going concern, prospects for future regulatory approval of NurOwn^®, whether BrainStorm's future interactions with the FDA will have productive outcomes, the impacts of the COVID-19 pandemic on our clinical trials, supply chain, and operations, and other factors detailed in BrainStorm's annual report on Form 10-K and quarterly reports on Form 10-Q available at http://www.sec.gov. These factors should be considered carefully, and readers should not place undue reliance on BrainStorm's forward-looking statements. The forward-looking statements contained in this press release are based on the beliefs, expectations, and opinions of management as of the date of this press release. We do not assume any obligation to update forward-looking statements to reflect actual results or assumptions if circumstances or management's beliefs, expectations or opinions should change, unless otherwise required by law. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance, or achievements.

CONTACTS

Investor Relations:
John Mullaly
LifeSci Advisors, LLC
Phone: +1 617-429-3548
jmullaly@lifesciadvisors.com

Media:
Lisa Guiterman
lisa.guiterman@gmail.com 

Logo: https://mma.prnewswire.com/media/1166536/BrainStorm_Logo.jpg

View original content:https://www.prnewswire.com/news-releases/brainstorm-cell-therapeutics-to-present-at-biotech-showcase-2023-301714183.html

SOURCE BrainStorm Cell Therapeutics Inc.

FAQ

What will BrainStorm Cell Therapeutics present at Biotech Showcase 2023?

BrainStorm Cell Therapeutics will present a corporate and clinical overview at Biotech Showcase 2023 on January 9, 2023, at 10:30 a.m. PT.

Who are the presenters at the Biotech Showcase 2023?

The presenters will be Chaim Lebovits, President and CEO, and Stacy Lindborg, Co-CEO of BrainStorm Cell Therapeutics.

How can investors attend the Biotech Showcase presentation?

Investors can attend the presentation in person or view it via a webcast on the Biotech Showcase platform.

What is the focus of BrainStorm Cell Therapeutics?

BrainStorm Cell Therapeutics focuses on developing adult stem cell therapeutics for debilitating neurodegenerative diseases like ALS.

What is NurOwn technology and its status?

NurOwn technology by BrainStorm Cell Therapeutics has received orphan drug designation from the FDA and EMA for treating amyotrophic lateral sclerosis (ALS).